HomeMedicineGeneticsA New Therapeutic Treatment for Cystic Fibrosis

A New Therapeutic Treatment for Cystic Fibrosis

Since the discovery of cystic fibrosis (CF) in 1938, there have been significant increases in life expectancy for those with CF.

Treatments such as antibiotics and physical therapy are responsible for the increased life expectancy into a person’s 30s.4 

However, these treatments still have limits as they do not directly target the problem behind CF – a genetic mutation. Nevertheless, a new study shows that with gene therapy, people with cystic fibrosis can alleviate symptoms while improving their quality of life. 

What is cystic fibrosis?

Cystic fibrosis is commonly linked to a genetic mutation relating to a protein called cystic fibrosis transmembrane conductance regulator (CFTR).1 The gene mutation is often the result of faulty instructions.

This mutation causes low production of the protein or its absence altogether. 

This protein is essential as it balances the water movement in tissues and produces mucus, sweat, saliva, tears, and digestive enzymes.2 Low levels of this protein cause the irregular function of the lungs, pancreas, liver, intestine, and reproductive organs1

Patients with CF often produce an excess amount of mucus with less control over the balance of water in tissues. This mucus traps bacteria, causing infection and inflammation in the airways.3 

A promising treatment for cystic fibrosis

Results of a recent clinical trial study showed that the use of antisense oligonucleotides (ASO) – molecules that control protein levels in cells, could create functioning versions of CFTR.5

The study focused on gene therapy using ASOs to make instructions in cells to create imperfect versions of CFTR

These imperfect versions of CFTR were able to improve the function of lung cells. These results are promising in advancing treatments for those with cystic fibrosis. 

Scientists are hopeful that through the use of ASO, there may be a way to have tailored therapies unique to an individual, paving the road to more personalized medicines. 

References 

  1. Naehrig, S., Chao, C.-M., & Naehrlich, L. (2017). Cystic fibrosis. Deutsches Ärzteblatt International. https://doi.org/10.3238/arztebl.2017.0564 
  2. Liou, T. G. (2019). The clinical biology of cystic fibrosis transmembrane regulator protein. Chest, 155(3), 605–616. https://doi.org/10.1016/j.chest.2018.10.006 
  3. Bell, S. C., Mall, M. A., Gutierrez, H., Macek, M., Madge, S., Davies, J. C., Burgel, P.-R., Tullis, E., Castaños, C., Castellani, C., Byrnes, C. A., Cathcart, F., Chotirmall, S. H., Cosgriff, R., Eichler, I., Fajac, I., Goss, C. H., Drevinek, P., Farrell, P. M., … Ratjen, F. (2020). The future of cystic fibrosis care: A global perspective. The Lancet Respiratory Medicine, 8(1), 65–124. https://doi.org/10.1016/s2213-2600(19)30337-6 
  4. Shteinberg, M., Haq, I. J., Polineni, D., & Davies, J. C. (2021). Cystic fibrosis. The Lancet, 397(10290), 2195–2211. https://doi.org/10.1016/s0140-6736(20)32542-3 
  5. Kim, Y.J., Nomakuchi, T., Papaleonidopoulou, F. et al. Gene-specific nonsense-mediated mRNA decay targeting for cystic fibrosis therapy. Nat Commun 132978 (2022). https://doi.org/10.1038/s41467-022-30668-y
Marianne Polvorosa
Marianne Polvorosa
As a curious child, I always had a desire to learn about the world around me, which eventually led me to the world of science. Currently, I am a 4th-year Biology major at Toronto Metropolitan University as a candidate for a Bachelor of Science. With my major, I have found that my interests lay in research for molecular biology and it has a large impact on the medical industry. This has then led to me this role at Medical News Bulletin, as I desired to be able to communicate my knowledge with the rest of the world.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

SUBSCRIBE TO OUR NEWSLETTERS

Stay Connected
10,288FansLike
820FollowersFollow
249FollowersFollow
2,787FollowersFollow

Article of the month

ANKTIVA Boosts BCG for Bladder Cancer

The FDA has approved the immunotherapy-boosting drug, ANKTIVA, to be used with the existing immunotherapy drug, Bacillus Calmette-Guerin (BCG). This new therapy is a...

Joke Of The Day

Doctor to the patient: Have you ever had chicken pox? Patient: No, but I have had chicken nuggets.

ADVERTISE WITH US

error: Content is read-only and copy-protected.